Rhumbline Advisers Eliem Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 27,740 shares of ELYM stock, worth $114,011. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,740
Previous 8,233
236.94%
Holding current value
$114,011
Previous $58,000
143.1%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ELYM
# of Institutions
69Shares Held
53.1MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.23% of portfolio
-
Janus Henderson Group PLC London, X03.61MShares$14.8 Million0.01% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.61MShares$10.7 Million7.7% of portfolio
-
Boxer Capital, LLC San Diego, CA2.6MShares$10.7 Million0.7% of portfolio
-
Deep Track Capital, LP Greenwich, CT2.17MShares$8.92 Million0.41% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...